TCRT insider filings
Alaunos Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-15. Screen TCRT transaction legs live →
Insider transaction summary — last 90 days
2026-07-26 to 2026-10-24, from the filings listed below: 10 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
Recent insider filings — Alaunos Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-15 | 3 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Fairmount Healthcare Co-Invest VII L.P. — Director, 10% owner Kiselak Tomas — 10% owner Harwin Peter Evan — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-08 | 4 | Postma Robert W — Director | Grant/award (A): 21,829 @ $0.74 | EDGAR |
| 2026-10-08 | 4 | Vieser Jaime — Director | Grant/award (A): 22,669 @ $0.74 | EDGAR |
| 2026-10-08 | 4 | Weis Holger — CEO | Grant/award (A): 23,564 @ $0.74 | EDGAR |
| 2026-10-08 | 4 | Jerman Michael Allen — Director | Grant/award (A): 20,990 @ $0.74 | EDGAR |
| 2026-08-11 | 4 | Weis Holger — CEO | Grant/award (A): 4,363 @ $2.01 | EDGAR |
| 2026-07-27 | 4 | Jerman Michael Allen — Director | Grant/award (A): 8,138 @ $1.92 | EDGAR |
| 2026-07-27 | 4 | Vieser Jaime — Director | Grant/award (A): 8,789 @ $1.92 | EDGAR |
| 2026-07-27 | 4 | Postma Robert W — Director | Grant/award (A): 8,463 @ $1.92 | EDGAR |
| 2026-07-27 | 4 | Weis Holger — CEO | Grant/award (A): 4,568 @ $1.92 | EDGAR |
| 2026-07-02 | 4 | Weis Holger — Chief Executive Officer | Grant/award (A): 3,880 @ $2.26 | EDGAR |
| 2026-06-17 | 4 | Weis Holger — Chief Executive Officer | Grant/award (A): 7,761 @ $2.26 | EDGAR |
| 2026-05-27 | 4 | Weis Holger — Chief Executive Officer | Grant/award (A): 3,700 @ $2.37 | EDGAR |
| 2026-05-01 | 4 | Vieser Jaime — Director | Grant/award (A): 6,515 @ $2.59 | EDGAR |
| 2026-05-01 | 4 | Postma Robert W — Director | Grant/award (A): 6,274 @ $2.59 | EDGAR |
| 2026-05-01 | 4 | Jerman Michael Allen — Director | Grant/award (A): 6,032 @ $2.59 | EDGAR |
| 2026-01-15 | 4 | Jerman Michael Allen — Director | Grant/award (A): 5,406 @ $2.89 | EDGAR |
| 2026-01-15 | 4 | Postma Robert W — Director | Grant/award (A): 5,622 @ $2.89 | EDGAR |
| 2026-01-15 | 4 | Vieser Jaime — Director | Grant/award (A): 5,839 @ $2.89 | EDGAR |
| 2025-11-26 | 4 | Vieser Jaime — Director | Grant/award (A): 5,340 @ $3.16 | EDGAR |
| 2025-11-26 | 4 | Postma Robert W — Director | Grant/award (A): 5,142 @ $3.16 | EDGAR |
| 2025-11-26 | 4 | Jerman Michael Allen — Director | Grant/award (A): 4,183 @ $3.16 | EDGAR |
| 2025-08-20 | 4 | Groenewald Ferdinand — Vice President of Finance | Grant/award (A): 10,775 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4 | Weis Holger — Chief Executive Officer, Director | Grant/award (A): 13,676 (derivative) @ $0 | EDGAR |
| 2025-07-17 | 4 | Jerman Michael Allen — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | Postma Robert W — Director | Grant/award (A): 4,050 @ $0 · Grant/award (A): 6,400 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | Vieser Jaime — Director | Grant/award (A): 3,400 @ $0 · Grant/award (A): 6,400 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | Weis Holger — Chief Executive Officer, Director | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Vieser Jaime — Director | Purchase (P): 250 (derivative) @ $4.49 | EDGAR |
| 2025-06-26 | 4 | Postma Robert W — Director | Grant/award (A): 20,804 @ $2.92 · Purchase (P): 500 (derivative) @ $2.76 · Purchase (P): 600 (derivative) @ $4.49 | EDGAR |
| 2025-04-15 | 4 | Postma Robert W — Director | Grant/award (A): 20,804 @ $2.92 · Purchase (P): 500 (derivative) @ $2.76 | EDGAR |
| 2025-04-15 | 4 | Weis Holger — Director | Grant/award (A): 10,904 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Vieser Jaime — Director | Grant/award (A): 17,465 @ $0 | EDGAR |
| 2025-04-01 | 4 | Hogue Dale Curtis Jr. — See Remarks, Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Lackey Melinda — Legal & Administration | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Groenewald Ferdinand — VP, Finance | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Vieser Jaime — Director | Sale (S): 2,182 @ $2.01 · Sale (S): 818 @ $2 | EDGAR |
| 2024-08-16 | 4 | Groenewald Ferdinand — VP, Finance | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2024-08-16 | 4 | Lackey Melinda — Legal & Administration | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Hofmeister Robert — Director | Grant/award (A): 12,800 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Weis Holger — Director | Grant/award (A): 19,200 (derivative) @ $0 · Grant/award (A): 4,524 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Vieser Jaime — Director | Grant/award (A): 12,800 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Postma Robert W — Director | Grant/award (A): 12,800 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Hogue Dale Curtis Jr. — Interim CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Hogue Dale Curtis Jr. — Director | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 41,667 (derivative) @ $0 | EDGAR |
| 2023-09-05 | 4 | Boyle Kevin S. Sr. — Chief Executive Officer, Director | Sale (S): 68,014 @ $0.14 | EDGAR |
| 2023-06-08 | 4 | Thistle Mary — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Huang James — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Vieser Jaime — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Weis Holger — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Alaunos Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-10-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-17 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TCRT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs